Pfizer's Dividend Faces Big Questions. Here Are 3 Reasons It Should Survive.
Income investors shouldn't be too worried about the pharma giant cutting its dividend.
Overview
Pfizer's (NYSE: PFE) forward dividend yield currently tops 6.2%. You can count the number of S&P 500 (SNPINDEX: ^GSPC) members with higher yields on your fingers -- and have several fingers to spare.
Does Pfizer's dividend program face big questions? Absolutely. However, that doesn't mean the drugmaker's dividend is in imminent jeopardy. Here are three reasons Pfizer's dividend should survive.
Image source: Getty Images.
Details
Source
Originally published at www.fool.com.
Related Articles
- Why the S&P 500 could still advance after a Fed hike, according to a Wall Street strategist
- ‘I’m burned out’: I’m constantly helping my cousin who is running out of money. Is it too much to expect his sister to help?
- Investors say this unloved market is ‘not a bad place to hide' as volatility rages on
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.